Blog | Page 20 of 23 | The Myositis Association

Lenabasum progresses to Phase 3 clinical trials

July 25, 2018January 16, 2019

Corbus Pharmaceuticals announced today that they will proceed with a Phase 3 clinical trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (DM).

Lenabasum receives Orphan Drug Designation for DM

July 23, 2018January 16, 2019

Corbus Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoidmimetic drug, for the treatment of dermatomyositis, systemic sclerosis, and other conditions.

Good news and bad news for DM research

June 13, 2018January 16, 2019

DM research moves forward as two clinical trials testing medications for this form of myositis report outcomes today.

TMA earns Charity Navigator’s 4-star rating

June 1, 2018December 19, 2018

The Myositis Association is pleased to announce that it has once again received a 4-star rating from Charity Navigator.

TMA in 25 Words

May 15, 2018December 19, 2018

May is Myositis Awareness Month. This year, TMA also celebrates 25 years as Your Myositis Association. In recognition of this amazing achievement in the rare disease world, TMA invited its members to describe TMA in 25 words (more or less).